Connor, Clark & Lunn Investment Management Ltd.

Position in TARS — Tarsus Pharmaceuticals, Inc.

CIK 1596800 VANCOUVER, A1

Position in TARS

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$5,725,588

-$2,091,717 QoQ

Shares Held

90,969

-18.4% QoQ

Ownership

0.207%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#61

of 256 holders

Holding Since

Sep 2023

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $648,992,404 across 104 Biotechnology names. TARS ranks #27 (0.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$5,725,588	90,969	-18.4%	Shares	Sole	2026-08-13
2026-03-31	$7,817,305	111,437	-35.7%	Shares	Sole	2026-05-11
2025-12-31	$14,187,757	173,275	+66.9%	Shares	Sole	2026-02-10
2025-09-30	$6,169,487	103,811	+71.6%	Shares	Sole	2025-11-13
2025-06-30	$2,450,652	60,495	+28.5%	Shares	Sole	2025-08-07
2024-09-30	$1,547,803	47,060	-44.8%	Shares	Sole	2024-11-08
2024-06-30	$2,319,079	85,323	-12.1%	Shares	Sole	2024-08-09
2024-03-31	$3,527,658	97,047	+7.7%	Shares	Sole	2024-05-09
2023-12-31	$1,824,180	90,083	+121.3%	Shares	Sole	2024-02-09
2023-09-30	$723,256	40,701	—	Shares	Sole	2023-11-13
No filing history on record for this holder in this stock.